Quote Request
Therapeutics Vaccine Development for Pancreatic Cancer
Cancer vaccines offer a promising approach to trigger specific and long-lasting immune responses against tumor antigens. These vaccines have several advantages, including minimal non-specific effects, low toxicity, and the ability to induce lasting immune memory. Alfa Cytology specializes in pancreatic cancer (PC) vaccine research and development, offering services in creating therapeutic vaccines, including whole-cell, peptide-based, and dendritic cell-based PC vaccines.
Overview of Therapeutic Vaccines for Pancreatic Cancer
Due to its systemic and aggressive nature, complex mutational environment, desmoplastic stroma, and effective immunosuppressive tumor microenvironment (TME), PC is highly resistant to chemotherapy and radiotherapy, with poorer outcomes compared to other solid tumors and lack of effective therapeutic treatments to cure them. Therefore, there is an urgent need to develop new, effective and well-tolerated therapies for the treatment of this disease, and immunotherapy is an obvious area to explore. In the broad field of immunotherapy, cancer vaccines are a promising approach because of their effectiveness, safety and low cost. To date, a multitude of vaccines have been studied in PC, involving whole-cancer cells, dendritic cells (DCs), specific peptides, nucleic acids, and so on. As for antigen targets, mutated KRAS, mucin-1 (MUC1), mesothelin, Wilms' tumor 1 (WT1), and carcinoembryonic antigen (CEA) are the most attractive targets.
Fig. 1 Classification of existing pancreatic cancer vaccines. (Huang X, et al., 2022)
Our Services
Alfa Cytology has an in-depth understanding of the tumor immunological profile of pancreatic cancer, particularly intra-tumor heterogeneity, tumor-microenvironment crosstalk, and microenvironmental instability. Therefore, we can help our clients to achieve precise and feasible development applications of PC vaccines and improve the efficacy and safety of related vaccines.
Harness the power of whole tumor cells to generate a comprehensive immune response against pancreatic cancer.
Utilize iPSC technology to train the immune system with cells resembling pancreatic tumors for targeted cancer therapy
Activate T-cells specifically against pancreatic cancer by leveraging the antigen-presenting capabilities of dendritic cells.
Induce a precise immune response with our peptide-based vaccines, designed to target specific tumor antigens in pancreatic cancer.
Develop custom mRNA vaccines that instruct your cells to produce tumor antigens, leading to a robust immune attack on pancreatic cancer.
Implement DNA vaccines that encode tumor antigens, prompting an immune system response specifically tailored to fight pancreatic cancer.
Why Choose Us?
Tailored Solutions
Advanced Technology
Professional Expertise
Collaborative Approach
As one of the leading service providers in the field of PC research and drug development, we continuously challenge ourselves and strive to offer our customers the finest service. If you are interested in learning more about our PC vaccine development services, please feel free to contact us. We look forward to working with you!
Reference
- Huang X, Zhang G, Tang TY, Gao X, Liang TB. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil Med Res. 2022 Oct 13;9(1):53.
